Targeted delivery of nanoparticles for the treatment of lung diseases

Advanced Drug Delivery Reviews

Volumn 60, Issue 8, 2008, Pages 863-875

  Azarmi, Shirzad ^a,b   Roa, Wilson H ^a   Löbenberg, Raimar ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Aerosol; Colloidal delivery; Lung cancer; Nanoparticle; Nanotoxicology; Pulmonary delivery; Tuberculosis

Indexed keywords

AEROSOLS; NANOPARTICLES; ONCOLOGY; PULMONARY DISEASES;

NANOTOXICOLOGICAL ASPECTS; PHARMACEUTICAL SCIENCES;

DRUG DELIVERY;

2 CYANOACRYLIC ACID HEXYL ESTER; ALBUMIN; ALBUMIN I 125; AZIDOTHYMIDINE C 14; BOVINE SERUM ALBUMIN; COLISTIN; CYANOACRYLATE DERIVATIVE; DIAZEPAM; DOXORUBICIN; DRUG CARRIER; EPIRUBICIN; GELATIN; HEXYLCYANOACRYLATE C 14; MALONIC ACID DERIVATIVE; METHACRYLIC ACID DERIVATIVE; METHOTREXATE; MONOCLONAL ANTIBODY; NANOPARTICLE; PACLITAXEL; POLOXAMINE 908; POLYHYXYLCYANOACRYLATE C 14; POLYLACTIC ACID C 14; POLYMETHACRYLIC ACID DERIVATIVE; POLYSORBATE 80; POLYSTYRENE DERIVATIVE; RADIOPHARMACEUTICAL AGENT; SURFACTANT; TUBERCULOSTATIC AGENT; UNINDEXED DRUG; ZIDOVUDINE;

AREA UNDER THE CURVE; CLINICAL TRIAL; DIAGNOSTIC VALUE; DRUG ACCUMULATION; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG TISSUE LEVEL; DRY POWDER; HUMAN; LIPOSOMAL GENE DELIVERY SYSTEM; LUNG DISEASE; LUNG NON SMALL CELL CANCER; LUNG TUBERCULOSIS; NANOTOXICOLOGY; NEBULIZATION; NONHUMAN; PARTICLE SIZE; PARTICULATE MATTER; PRIORITY JOURNAL; RETICULOENDOTHELIAL SYSTEM; REVIEW; SINGLE DRUG DOSE;

ANIMALS; ANTIBODIES, MONOCLONAL; DRUG DELIVERY SYSTEMS; GENE TRANSFER TECHNIQUES; HUMANS; LUNG; LUNG DISEASES; MAGNETICS; NANOPARTICLES;

EID: 42649137232     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.addr.2007.11.006     Document Type: Review

References (96)

1. Ely L., Roa W., Finlay W.H., and Löbenberg R. Effervescent dry powder for respiratory drug delivery. Eur. J. Pharm. Biopharm. 65 3 (2007) 346-353
2. Quattrin T. Inhaled insulin: recent advances in the therapy of Type 1 and 2 diabetes. Expert Opin. Pharmacother. 5 12 (2004) 2597-2604
3. Patton J.S., and Platz R.M. Pulmonary delivery of peptides and proteins for systemic action. Adv. Drug Deliv. Rev. 8 (1992) 179-196
4. Clark A. Formulation of proteins and peptides for inhalation. Drug Deliv. Syst. Sci. 2 (2002) 73-77
5. Courrier H.M., Butz N., and Vandamme T.F. Pulmonary drug delivery systems: recent developments and prospects. Crit. Rev. Ther. Drug Carr. Syst. 19 (2002) 425-498
6. Gill S., Löbenberg R., Ku T., Azarmi S., Roa W., and Prenner E.J. Nanoparticles: characteristics, mechanisms of action and toxicity in pulmonary drug delivery-a review. J. Biomed. Nanotechnol. 3 (2007) 107-119
7. Edwards D.A., Hanes J., Caponetti G., Hrkach J., Ben-Jebria A., Eskew M.L., Mintzes J., Deaver D., Lotan N., and Langer R. Large porous particles for pulmonary drug delivery. Science 276 (1997) 1868-1871
8. Tsapis N., Bennett D., Jackson B., Weitz D.A., and Edwards D.A. Trojan particles: large porous carriers of nanoparticles for drug delivery. Proc. Natl. Acad. Sci. 99 (2002) 12001-12005
9. Niven R.W. Delivery of biotherapeutics by inhalation aerosol. Crit. Rev. Ther. Drug Carr. Syst. 12 (1995) 151-231
10. Taylor G., and Kellaway I. Pulmonary drug delivery. In: Hillery A., Lloyd A., and Swarbrick J. (Eds). Drug Delivery and Targeting (2001), Taylor & Francis, New York 269-300
11. Bosquillon C., Lombry C., Preat V., and Vanbever R. Influence of formulation excipients and physical characteristics of inhalation dry powders on their aerosolization performance. J. Control. Release 70 (2001) 329-339
12. Kreuter J., Tauber U., and Illi V. Distribution and elimination of poly (methyl-2-14C-methacrylate) nanoparticle radioactivity after injection in rats and mice. J. Pharm. Sci. 68 11 (1979) 1443-1447
13. Gipps E.M., Arshady R., and Kreuter J. Distribution of polyhexyl cyanoacrylate nanoparticles in nude mice bearing human osteosarcoma. J. Pharm. Sci. 75 3 (1986) 256-258
14. Waser P.G., Muller U., Kreuter J., Berger S., Munz K., Kaiser E., and Pfluger B. Localization of colloidal particles (liposomes, hexylcyanoacrylate nanoparticles and albumin nanoparticles) by histology and autoradigraphy in mice. Int. J. Pharm. 39 (1987) 213-227
15. Kreuter J. Evaluation of nanoparticles as drug-delivery systems III: materials, stability, toxicity, possibilities of targeting, and use. Pharm. Acta Helv. 58 9-10 (1983) 242-250
16. Rolland A., Collet B., Le Verge R., and Toujas L. Blood clearance and organ distribution of intravenously administered polymethacrylic nanoparticles in mice. J. Pharm. Sci. 78 6 (1989) 481-484
17. Bazile D.V., Ropert C., Huve P., Verrecchia T., Marlard M., Frydman A., Veillard M., and Spenlehauer G. Body distribution of fully biodegradable [14C]-poly (lactic acid) nanoparticles coated with albumin after parenteral administration to rats. Biomaterials 13 15 (1992) 1093-1102
18. Lescure F., Seguin L.C., Breton P., Bourrinet P., Roy D., and Couvreur P. Preparation and characterization of novel poly (methylidene malonate 2.1.2.)-made nanoparticles. Pharm. Res. 11 9 (1994) 1270-1277
19. Simon B.H., Ando H.Y., and Gupta P.K. Circulation time and body distribution of 14C-labeled amino-modified polystyrene nanoparticles in mice. J. Pharm. Sci. 84 10 (1995) 1249-1253
20. Page M.E., Pinto-Alphandary H., Chachaty E., Andremont A., and Couvreur P. Entrapment of colistin into polyhexylcyanoacrylate nanoparticles: preparation, drug release and tissue distribution in mice. S.T.P. Pharm. Sci. 6 4 (1996) 298-301
21. Leucuta S.E., Achim M., Risca R., and Postescu I.D. Preparation and pharmaceutical/pharmacokinetic characterization of liposomes and nanoparticles loaded with epirubicin. S.T.P. Pharm. Sci. 13 5 (2003) 291-297
22. Chen J.-H., Wang L., Ling R., Li Y., Wang Z., Yao Q., and Ma Z. Body distribution of nanoparticle-containing adriamycin injected into the hepatic artery of hepatoma-bearing rats. Dig. Dis. Sci. 49 7-8 (2004) 1170-1173
23. Teng K.Y., Lu Z., Wientjes M.G., and Au J.L.-S. Formulating paclitaxel in nanoparticles alters its disposition. Pharm. Res. 22 6 (2005) 867-874
24. Zara G.P., Cavalli R., Fundarò A., Bargoni A., Caputo O., and Gasco M.R. Pharmacokinetics of doxorubicin incorporated in solid lipid nanospheres (SLN). Pharmacol. Res. 40 3 (1999) 281-286
25. Santhi K., Dhanaraj S.A., Koshy M., Ponnusankar S., and Suresh B. Study of biodistribution of methotrexate-loaded bovine serum albumin nanospheres in mice. Drug Dev. Ind. Pharm. 26 12 (2000) 1293-1296
26. Löbenberg R., Araujo L., Von Briesen H., Rodgers E., and Kreuter J. Body distribution of azidothymidine bound to hexyl-cyanoacrylate nanoparticles after i.v. injection to rats. J. Control. Release 50 1-3 (1998) 21-30
27. Leu D., Manthey B., and Kreuter J. Distribution and elimination of coated polymethyl [2-14C]methacrylate nanoparticles after intravenous injection in rats. J. Pharm. Sci. 73 10 (1984) 1433-1437
28. Gulyaev A.E., Gelperina S.E., Skidan I.N., Antropov A.S., Kivman G.Ya., and Kreuter J. Significant transport of doxorubicin into the brain with polysorbate 80-coated nanoparticles. Pharm. Res. 16 10 (1999) 1564-1569
29. Araujo L., Löbenberg R., and Kreuter J. Influence of the surfactant concentration on the body distribution of nanoparticles. J. Drug Target. 6 5 (1999) 373-385
30. Green M.R., Manikhas G.M., Orlov S., Afanasyev B., Makhson A.M., Bhar P., and Hawkins M.J. Abraxane®, a novel Cremophor®-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer. Ann. Oncol. 17 8 (2006) 1263-1268
31. Kohler G., and Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256 5517 (1975) 495-497
32. Garnett M.C. Targeted drug conjugates: principles and progress. Adv. Drug Deliv. Rev. 53 2 (2001) 171-216
33. Funaro A., Horenstein A.L., Santoro P., Cinti C., Gregorini A., and Malavasi F. Monoclonal antibodies and therapy of human cancers. Biotechnol. Adv. 18 5 (2000) 385-401
34. Trail P.A., and Bianchi A.B. Monoclonal antibody drug conjugates in the treatment of cancer. Curr. Opin. Immunol. 11 5 (1999) 584-588
35. Trail P.A., King H.D., and Dubowchik G.M. Monoclonal antibody drug immunoconjugates. Cancer Immunol. Immunother. 52 5 (2003) 328-337
36. Lambert J.M. Drug-conjugated monoclonal antibodies for treatment of cancer. Curr. Opin. Pharmacol. 5 5 (2005) 543-549
37. Akasaka Y., Ueda H., Takayama K., Machida Y., and Nagai T. Preparation and evaluation of bovine serum albumin nanospheres coated with monoclonal antibodies. Drug Des. Deliv. 3 1 (1988) 85-97
38. Muro S., and Muzykantov V.R. Targeting of antioxidant and anti-thrombotic drugs to endothelial cell adhesion molecules. Curr. Pharm. Des. 11 18 (2005) 2383-2401
39. Wiewrodt R., Thomas A.P., Cipelletti L., Christofidou-Solomidou M., Weitz D.A., and Feinstein S.I. Size-dependent intracellular immunotargeting of therapeutic cargoes into endothelial cells. Blood 99 (2002) 912-922
40. Muro S., Wiewrodt R., Thomas A., Koniaris L., Albelda S.M., and Muzykantov V.R. A novel endocytic pathway induced by clustering endothelial ICAM-1 or PECAM-1. J. Cell Sci. 116 (2003) 1599-1609
41. Jani P., Halbert G.W., Langridge J., and Florence A.T. The uptake and translocation of latex nanospheres and microspheres after oral administration to rats. J. Pharm. Pharmacol. 41 12 (1989) 809-812
42. Jani P., Halbert G.W., Langridge J., and Florence A.T. Nanoparticle uptake by the rat gastrointestinal mucosa: quantitation and particle size dependency. J. Pharm. Pharmacol. 42 12 (1990) 821-826
43. Löbenberg R., Araujo L., and Kreuter J. Body distribution of azidothymidine bound to nanoparticles after oral administration. Eur. J. Pharm. Biopharm. 44 2 (1997) 127-132
44. Araujo L., Sheppard M., Löbenberg R., and Kreuter J. Uptake of PMMA nanoparticles from the gastrointestinal tract after oral administration to rats: modification of the body distribution after suspension in surfactant solutions and in oil vehicles. Int. J. Pharm. 176 2 (1999) 209-224
45. Santra S., Dutta D., Walter G.A., and Moudgil B.M. Fluorescent nanoparticle probes for cancer imaging. Technol. Cancer Res. Treat. 4 6 (2005) 593-602
46. Groneberg D.A., Giersig M., Welte T., and Pison U. Nanoparticle-based diagnosis and therapy. Curr. Drug Targets 7 6 (2006) 643-648
47. Sunderland C.J., Steiert M., Talmadge J.E., Derfus A.M., and Barry S.E. Targeted nanoparticles for detecting and treating cancer. Drug Dev. Res. 67 1 (2006) 70-93
48. Ketai L.H., Muggenberg B.A., McIntire G.L., Bacon E.R., Rosenberg R., Losco P.E., Toner J.L., Nikula K.J., and Haley P. CT imaging of intrathoracic lymph nodes in dogs with bronchoscopically administered iodinated nanoparticles. Acad. Radiol. 6 1 (1999) 49-54
49. Cragin M.D., Webber M.M., Victery W.K., and Pintauro D. Technique for the rapid preparation of lung scan particles using 99mTc-sulfur and human serum albumin. J. Nucl. Med. 10 (1969) 621-623
50. Löbenberg R., and Kreuter J. Macrophage targeting of azidothymidine: a promising strategy for AIDS therapy. AIDS Res. Human Retroviruses 12 18 (1996) 1709-1715
51. Gelperina S., Kisich K., Iseman M.D., and Heifets L. The potential advantages of nanoparticle drug delivery systems in chemotherapy of tuberculosis. Am. J. Respir. Crit. Care Med. 172 12 (2005) 1487-1490
52. Anisimova Y.V., Gelperina S.I., Peloquin C.A., and Heifets L.B. Nanoparticles as antituberculosis drugs carriers: effect on activity against Mycobacterium tuberculosis in human monocyte-derived macrophages. J. Nanopart. Res. 2 2 (2000) 165-171
53. Pandey R., and Khuller G.K. Subcutaneous nanoparticle-based antitubercular chemotherapy in an experimental model. J. Antimicrob. Chemother. 54 1 (2004) 266-268
54. Pandey R., Sharma S., and Khuller G.K. Oral solid lipid nanoparticle-based antitubercular chemotherapy. Tuberculosis 85 5-6 (2005) 415-420
55. Johnson C.M., Pandey R., Sharma S., Khuller G.K., Basaraba R.J., Orme I.M., and Lenaerts A.J. Oral therapy using nanoparticle-encapsulated antituberculosis drugs in guinea pigs infected with Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 49 10 (2005) 4335-4338
56. Pandey R., Sharma S., and Khuller G.K. Chemotherapeutic efficacy of nanoparticle encapsulated antitubercular drugs. Drug Deliv. 13 4 (2006) 287-294
57. Woodle M.C., and Lu P.Y. Nanoparticles deliver RNAi therapy. Mater. Today 8 8 SUPPL (2005) 34-41
58. Boeckle S., and Wagner E. Optimizing targeted gene delivery: chemical modification of viral vectors and synthesis of artificial virus vector systems. AAPS J. 8 4 (2006) E731-E742
59. Gopalan B., Ito I., Branch C.D., Stephens C., Roth J.A., and Ramesh R. Nanoparticle based systemic gene therapy for lung cancer: molecular mechanisms and strategies to suppress nanoparticle-mediated inflammatory response. Technol. Cancer Res. Treat. 3 6 (2004) 647-657
60. Kaul G., and Amiji M. Tumor-targeted gene delivery using poly (ethylene glycol)-modified gelatin nanoparticles: in vitro and in vivo studies. Pharm. Res. 22 6 (2005) 951-961
61. Fink T.L., Klepcyk P.J., Oette S.M., Gedeon C.R., Hyatt S.L., Kowalczyk T.H., Moen R.C., and Cooper M.J. Plasmid size up to 20 kbp does not limit effective in vivo lung gene transfer using compacted DNA nanoparticles. Gene Ther. 13 13 (2006) 1048-1051
62. Li S.-D., and Huang L. Targeted delivery of antisense oligodeoxynucleotide and small interference RNA into lung cancer cells. Mol. Pharm. 3 5 (2006) 579-588
63. Mykhaylyk O., Dudchenko N., and Dudchenko A. Doxorubicin magnetic conjugate targeting upon intravenous injection into mice: high gradient magnetic field inhibits the clearance of nanoparticles from the blood. J. Magn. Magn. Mater. 293 1 (2005) 473-482
64. Wu T., Hua M.-Y., Chen J.-P., Wei K.-C., Jung S.-M., Chang Y.-J., Jou M.-J., and Ma Y.-H. Effects of external magnetic field on biodistribution of nanoparticles: a histological study. J. Magn. Magn. Mater. 311 (2007) 372-375
65. Grenha A., Seijo B., and Remuñán-López C. Microencapsulated chitosan nanoparticles for lung protein delivery. Eur. J. Pharm. Sci. 25 4-5 (2005) 427-437
66. Sham J.O.-H., Zhang Y., Finlay W.H., Roa W.H., and Loebenberg R. Formulation and characterization of spray-dried powders containing nanoparticles for aerosol delivery to the lung. Int. J. Pharm. 269 2 (2004) 457-467
67. Kawashima Y., Serigano T., Hino T., Yamamoto H., and Takeuchi H. A new powder design method to improve inhalation efficiency of pranlukast hydrate dry powder aerosols by surface modification with hydroxypropylmethylcellulose phthalate nanospheres. Pharm. Res. 15 11 (1998) 1748-1752
68. Kawashima Y., Yamamoto H., Takeuchi H., Fujioka S., and Hinto T. Pulmonary delivery of insulin with nebulized dl-lactide/glycolide copolymer (PLGA) nanospheres to prolong hypoglycemic effect. J. Control. Release 62 (1999) 279-287
69. Dailey L.A., Kleemann E., Wittmar M., Gessler T., Schmehl T., Roberts C., Seeger W., and Kissel T. Surfactant-free, biodegradable nanoparticles for aerosol therapy based on the branched polyesters, DEAPA-PVAL-g-PLGA. Pharm. Res. 20 12 (2003) 2011-2020
70. Videira M.A., Botelho M.F., Santos A.C., Gouveia L.F., Pedroso De Lima J.J., and Almeida A.J. Lymphatic uptake of pulmonary delivered radiolabelled solid lipid nanoparticles. J. Drug Target. 10 8 (2002) 607-613
71. Pandey R., Sharma A., Zahoor A., Sharma S., Khuller G.K., and Prasad B. Poly (dl-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis. J. Antimicrob. Chemother. 52 6 (2003) 981-986
72. Pandey R., and Khuller G.K. Solid lipid particle-based inhalable sustained drug delivery system against experimental tuberculosis. Tuberculosis 85 4 (2005) 227-234
73. Yamamoto H., Kuno Y., Sugimoto S., Takeuchi H., and Kawashima Y. Surface-modified PLGA nanosphere with chitosan improved pulmonary delivery of calcitonin by mucoadhesion and opening of the intercellular tight junctions. J. Control. Release 102 2 (2005) 373-381
74. McConville J.T., Overhoff K.A., Sinswat P., Vaughn J.M., Frei B.L., Burgess D.S., Talbert R.L., Peters J.I., Johnston K.P., and Williams III R.O. Targeted high lung concentrations of itraconazole using nebulized dispersions in a murine model. Pharm. Res. 23 5 (2006) 901-911
75. Oberdorster G., Maynard A., Donaldson K., Castranova V., Fitzpatrick J., Ausman K., Carter J., Karn B., Kreyling W., Lai D., Olin S., Monteiro-Riviere N., Warheit D., and Yang H. Principles for characterizing the potential human health effects from exposure to nanomaterials: elements of a screening strategy. Part. Fibre Toxicol 2 (2005) (art. no. 8)
76. Driscoll K.E., Carter J.M., Howard B.W., Hassenbein D.G., Pepelko W., Baggs R.B., and Oberdoerster G. Pulmonary inflammatory, chemokine, and mutagenic responses in rats after subchronic inhalation of carbon black. Toxicol. Appl. Pharmacol. 136 (1996) 372-380
77. Heinrich U., Fuhst R., Rittinghausen S., Creutzenberg O., Bellmann B., Koch W., and Levsen K. Chronic inhalation exposure of Wistar rats and two different strains of mice to diesel engine exhaust, carbon black, and titanium dioxide. Inhal. Toxicol. 7 (1995) 533-556
78. Nikula K.J., Snipes M.B., Barr E.B., Griffith W.C., Henderson R.F., and Mauderly J.L. Comparative pulmonary toxicities and carcinogenicities of chronically inhaled diesel exhaust and carbon black in F344 rats. Fundam. Appl. Toxicol. 25 (1995) 80-94
79. Warheit D.B., Laurence B.R., Reed K.L., Roach D.H., Reynolds G.A.M., and Webb T.R. Comparative pulmonary toxicity assessment of single-wall carbon nanotubes in rats. Toxicol. Sci. 77 1 (2004) 117-125
80. Shvedova A.A., Murray A.R., Kisin E.R., Schwegler-Berry D., Kagan V.E., and Gandelsman V.Z. Exposure to carbon nanotube material: evidence of exposure-induced oxidant stress in human keratinocyte and bronchial epithelial cells. Free Radic. Res. 37 (2003) 97
81. Barlow P.G., Clouter-Baker A., Donaldson K., MacCallum J., and Stone V. Carbon black nanoparticles induce type II epithelial cells to release chemotaxins for alveolar macrophages. Part. Fibre Toxicol. 2 (2005) art. no. 11
82. Xia T., Kovochich M., Brant J., Hotze M., Sempf J., Oberley T., Sioutas C., Yeh J.I., Wiesner M.R., and Nel A.E. Comparison of the abilities of ambient and manufactured nanoparticles to induce cellular toxicity according to an oxidative stress paradigm. Nano Lett. 6 8 (2006) 1794-1807
83. Wiebert P., Sanchez-Crespo A., Falk R., Philipson K., Lundin A., Larsson S., Moller W., Kreyling W., and Svartengren M. No significant translocation of inhaled 35-nm carbon particles to the circulation in humans. Inhal. Toxicol. 18 10 (2006) 741-747
84. Lin W., Huang Y.-W., Zhou X.-D., and Ma Y. Toxicity of cerium oxide nanoparticles in human lung cancer cells. Int. J. Toxicol. 25 6 (2006) 451-457
85. Brown J.S., Zeman K.L., and Bennett W.D. Ultrafine particle deposition and clearance in the healthy and obstructed lung. Am. J. Respir. Crit. Care Med. 166 (2002) 1240-1247
86. Warheit D.B., Hansen J.F., Yuen I.S., Kelly D.P., Snajdr S.I., and Hartsky M.A. Inhalation of high concentrations of low toxicity dusts in rats results in impaired pulmonary clearance mechanisms and persistent inflammation. Toxicol. Appl. Pharmacol. 145 (1997) 10-22
87. Renwick L.C., Donaldson K., and Clouter A. Impairment of alveolar macrophage phagocytosis by ultrafine particles. Toxicol. Appl. Pharmacol. 172 2 (2001) 119-127
88. Möller W., Hofer T., Ziesenis A., Karg E., and Heyder J. Ultrafine particles cause cytoskeletal dysfunctions in macrophages. Toxicol. Appl. Pharmacol. 182 3 (2002) 197-207
89. Inoue K.-I., Takano H., Yanagisawa R., Hirano S., Sakurai M., Shimada A., and Yoshikawa T. Effects of airway exposure to nanoparticles on lung inflammation induced by bacterial endotoxin in mice. Environ. Health Perspect. 114 9 (2006) 1325-1330
90. Sayes C.M., Reed K.L., and Warheit D.B. Assessing toxicity of fine and nanoparticles: comparing in vitro measurements to in vivo pulmonary toxicity profiles. Toxicol. Sci. 97 1 (2007) 163-180
91. Takenaka S., Karg E., Kreyling W., Lentner B., Moller W., Behnke-Semmler M., Jennen L., Walch A., Michalke B., Schramel P., Heyder J., and Schulz H. Distribution pattern of inhaled ultrafine gold particles in the rat lung. Inhal. Toxicol. 18 10 (2006) 733-740
92. Forbes B., and Ehrhardt C. Human respiratory epithelial cell culture for drug delivery applications. Eur. J. Pharm. Biopharm. 60 (2005) 193-205
93. Kim K.J., Borok Z., and Crandall E.D. A useful in vitro model for transport studies of alveolar epithelial barrier. Pharm. Res. 18 (2001) 253-255
94. Brzoska M., Langer K., Coester C., Loitsch S., Wagner T.O.F., and Mallinckrodt C.V. Incorporation of biodegradable nanoparticles into human airway epithelium cells - in vitro study of the suitability as a vehicle for drug or gene delivery in pulmonary diseases. Biochem. Biophys. Res. Commun. 318 2 (2004) 562-570
95. Dailey L.A., Jekel N., Fink L., Gessler T., Schmehl T., Wittmar M., Kissel T., and Seeger W. Investigation of the proinflammatory potential of biodegradable nanoparticle drug delivery systems in the lung. Toxicol. Appl. Pharmacol. 215 1 (2006) 100-108
96. Stuart D., Löbenberg R., Ku T., Azarmi S., Ely L., Roa W., and Prenner E.J. Biophysical investigation of nanoparticle interactions with lung surfactant model systems. J. Biomed. Nanotech. 2 3-4 (2006) 245-252